• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics Signs Vita Genomics of Taiwan to Database Subscription Deal
Vita Genomics is Celera’s First Subscriber in Taiwan

Rockville, MD, USA and Taipei, Taiwan - March 19, 2001

Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today that Vita Genomics, a newly established company based in Taiwan., has signed a multi-year subscription agreement. Vita Genomics’ researchers will access the Celera Discovery System™ to use Celera's integrated database products, bioinformatics systems, and other discovery tools to conduct genomics research. Financial terms of the agreement were not disclosed.

“This agreement with Vita Genomics is important as it is the first company in Taiwan to access Celera’s genomic databases,” said J. Craig Venter, Ph.D., Celera's president and chief scientific officer. “Through the Celera Discovery System, researchers worldwide have immediate desktop access to some of the most advanced tools and systems with which to analyze and interpret the Celera generated genomic and biological data as well as publicly available data. The ability to integrate these massive amounts of data through one system should allow scientists to find particular disease genes, better understand genetic variation and its role in disease, as well as gain insight into the function of proteins within the body.”

“We are very pleased to work with Celera Genomics, a premier genomics and biological information company,” said Ellson Chen, Ph. D., president and chief executive officer of Vita Genomics, and formerly a principal scientist at Celera. “Using Celera’s datasets, we intend to uncover targets for human diseases prevalent in the Taiwanese population as a basis for understanding the causes of disease in the Asia Pacific region and to develop and commercialize products for diagnosing, treating and preventing these diseases.”

The Celera Discovery System is an integrated, web-based discovery system that allows subscribers to use Celera generated databases, additional non-proprietary genome and biological datasets, computational tools and super-computing power to advance the discovery programs of researchers worldwide.

About Vita Genomics
Vita Genomics, Inc. (VG), a new business entity established by Taiwanese investors, plans to set up its operations initially in Taiwan..The company is organized and managed by a group of renowned American scientists and senior biotechnology /pharmaceutical executives of Chinese descent. VG’s business objective is to become a premier genomics-based biotechnology and biopharmaceutical company focused on improving biological products and understanding diseases prevalent in the Asia Pacific region. VG intends to achieve its objective in the following manner: 1) establish a state-of-the-art gene and drug discovery infrastructure; 2) develop a proprietary set of databases relevant to Asian-specific genotypes; 3) conduct highly-focused research efforts in major diseases prevalent among the Asian population; and 4) leverage infrastructure to meet needs for large-scale genomic analysis and product adaptation and improvement for Asian-specific markets. News releases by Vita Genomics will be available on the company's web site at www.vitagenomics.com.

About Celera
Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to be the definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, which all build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic and diagnostic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.